RGNX — Regenxbio Cashflow Statement
0.000.00%
Last trade - 00:00- $442.32m
- $399.27m
- $170.44m
- 40
- 23
- 30
- 20
Annual cashflow statement for Regenxbio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 128 | -280 | -263 | -227 | -194 |
| Depreciation | |||||
| Non-Cash Items | 41.3 | 45.9 | 38.7 | 32.2 | 42.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 40.2 | 14 | -10.9 | 5.53 | 11.8 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 219 | -207 | -218 | -173 | -124 |
| Capital Expenditures | -84.2 | -30.7 | -9.96 | -2.44 | -2.41 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -322 | 18.8 | 201 | 106 | -13.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -407 | -11.9 | 191 | 103 | -15.9 |
| Financing Cash Flow Items | -0.644 | 0 | -0.47 | -0.323 | 144 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 195 | -28.8 | -35 | 92.7 | 117 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.48 | -248 | -62.4 | 23 | -23.1 |